# reload+after+2024-01-20 06:46:37.528970
address1§60 Avenue Rockefeller
address2§Bâtiment Adénine
city§Lyon
zip§69008
country§France
phone§33 4 78 74 44 38
fax§33 4 78 75 56 29
website§https://www.erytech.com
industry§Biotechnology
sector§Healthcare
longBusinessSummary§PHAXIAM Therapeutics S.A., a biopharmaceutical company, focuses on developing treatments for resistant bacterial infections in France and the United States. It develops eryaspase, which is in Phase 3 clinical development for the treatment of second-line pancreatic cancer, and in Phase 2 stage for the treatment of triple-negative breast cancer and second-line acute lymphoblastic leukemia patients. The company also engages in developing a portfolio of phages targeting resistant and dangerous bacteria, which together account for more than two-thirds of resistant hospital-acquired infections, including staphylococcus aureus, escherichia coli, and pseudomonas aeruginosa. The company was formerly known as ERYTECH Pharma S.A. and changed its name to PHAXIAM Therapeutics S.A. in June 2023. PHAXIAM Therapeutics S.A. was incorporated in 2004 and is headquartered in Lyon, France.
fullTimeEmployees§49
companyOfficers§[{'maxAge': 1, 'name': 'Mr. Eric  Soyer Ph.D.', 'age': 57, 'title': 'Deputy CEO, Deputy GM, CFO & COO', 'yearBorn': 1966, 'fiscalYear': 2022, 'totalPay': 416025, 'exercisedValue': 0, 'unexercisedValue': 0}, {'maxAge': 1, 'name': 'Dr. Jérôme  Bailly Pharm.D.', 'age': 44, 'title': 'Deputy CEO, Deputy GM, Chief Quality Officer & Qualified Person', 'yearBorn': 1979, 'fiscalYear': 2022, 'totalPay': 271610, 'exercisedValue': 0, 'unexercisedValue': 0}, {'maxAge': 1, 'name': 'Mr. Thibaut du Fayet', 'age': 55, 'title': 'Chief Executive Officer', 'yearBorn': 1968, 'fiscalYear': 2022, 'exercisedValue': 0, 'unexercisedValue': 0}, {'maxAge': 1, 'name': 'Ms. Céline  Breda', 'age': 52, 'title': 'Chief Technology Officer', 'yearBorn': 1971, 'fiscalYear': 2022, 'exercisedValue': 0, 'unexercisedValue': 0}, {'maxAge': 1, 'name': 'Ms. Cindy  Fevre', 'title': 'Chief Scientific Officer', 'fiscalYear': 2022, 'exercisedValue': 0, 'unexercisedValue': 0}, {'maxAge': 1, 'name': 'Naomi  Eichenbaum', 'title': 'Director Investor Relations', 'fiscalYear': 2022, 'exercisedValue': 0, 'unexercisedValue': 0}, {'maxAge': 1, 'name': 'Ms. Anne-Cécile  Fumey', 'age': 48, 'title': 'Vice President of Human Resources', 'yearBorn': 1975, 'fiscalYear': 2022, 'exercisedValue': 0, 'unexercisedValue': 0}, {'maxAge': 1, 'name': 'Ms. Karine  Charton Ph.D.', 'title': 'Chief Business Officer', 'fiscalYear': 2022, 'exercisedValue': 0, 'unexercisedValue': 0}, {'maxAge': 1, 'name': 'Dr. Pascal  Birman', 'title': 'Chief Medical Officer', 'fiscalYear': 2022, 'exercisedValue': 0, 'unexercisedValue': 0}, {'maxAge': 1, 'name': 'Ms. Frederique  Vieville', 'title': 'Chief Regulatory Officer', 'fiscalYear': 2022, 'exercisedValue': 0, 'unexercisedValue': 0}]
compensationAsOfEpochDate§1672444800
maxAge§86400
priceHint§2
payoutRatio§0.0
beta§1.853
priceToSalesTrailing12Months§5.4256954
currency§USD
dateShortInterest§1702598400
exchange§NCM
quoteType§EQUITY
shortName§PHAXIAM Therapeutics S.A.
longName§PHAXIAM Therapeutics S.A.
firstTradeDateEpochUtc§1509024600
timeZoneFullName§America/New_York
timeZoneShortName§EST
uuid§6b2ad688-2bbe-3137-a891-b5e4b9904b69
gmtOffSetMilliseconds§-18000000
recommendationMean§3.0
recommendationKey§hold
grossMargins§1.0
ebitdaMargins§-2.57804
trailingPegRatio§None
